Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$318.0K-44.41%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sean McClain
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 140
- Beta
- 2.44
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 45.16
Financials
Revenue
$318.0K-44.4%Net Income
$-33.21MEBITDA
$-30.47MFree Cash Flow
$-27.57MEPS (diluted)
$-0.21Shares Outstanding (diluted)
157.47M+74.2%Operating Expenses
$31.78MCash & Debt
$201.14MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.80M | $-115.18M | $-0.84 |
| 2024 | $4.53M | $-103.11M | $-0.94 |
| 2023 | $5.72M | $-110.57M | $-1.20 |
| 2022 | $5.75M | $-104.90M | $-1.15 |
| 2021 | $4.78M | $-100.96M | $-1.11 |
| 2020 | $4.78M | $-14.35M | $-0.54 |
| 2019 | $2.06M | $-6.58M | $-0.07 |
Valuation
ABSIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-68.75%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·12d ago·Neutral
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·27d ago·Positive
Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade) Absci Corporation is upgraded to “Buy” following positive interim Phase 1 data for ABS-201 in androgenetic alopecia [AGA]. ABS-201 demonstrated an excellent PK profile, enabling infrequent dosing [2–3 injections per 6 months] and strong safety/tolerability in SAD cohorts. Upcoming catalysts include 13-week interim proof-of-concept data in 2H 2026 and 26-week topline results in early 2027 for ABS-201 in AGA.
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Absci to Participate in Upcoming Investor Conferences VANCOUVER, Wash. and NEW YORK, Sept.
View source ↗ - Newszacks.com·49d ago·Negative
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·55d ago·Negative
Absci Q2 Earnings Call Highlights Absci NASDAQ: ABSI outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis, while reporting a larger cash balance following a June equity offering and strategic investment from Eli Lilly.
View source ↗ - News247wallst.com·55d ago·Positive
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech) Anthropic is preparing what could be the largest IPO of 2026, and it's telling investors the pitch goes well beyond chatbots. According to the Wall Street Journal, "Anthropic is targeting a public debut in September or early October, people familiar with its plans said." In those same meetings, the company told some investors that it... The Biggest IPO of the Yea
View source ↗
Earnings
Mon, Nov 16(in 6 weeks)
Consensus estimate $-0.19 per share
Typical surprise -5.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.18 vs $-0.19beat
- Thu, May 7$-0.19 vs $-0.20beat
- Tue, Mar 24$-0.23 vs $-0.16miss
- Wed, Nov 12$-0.20 vs $-0.19miss
- Tue, Aug 12$-0.24 vs $-0.19miss
- Tue, May 13$-0.21 vs $-0.23beat
Estimates and results for ABSI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ABSI officers and directors.
- Bought
- $1.4m
- Sold
- $132k
8 trades
2 trades
- Szela Mary Tbought
- Pangalos Menelas Nbought
- Busch Andreasbought
- Pangalos Menelas Nbought
- Mcclain Seansold
- Jonasson Zachariahsold
- Van Houten Fransbought
- Pangalos Menelas Nbought
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ABSI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.